AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05820724
Drug: 18F- DCFPyl Injection
RxNorm normalized name: (18F)DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCFPyL is a PSMA imaging ligand that was developed to enhance the detection of small lesions in the prostate or other pelvic areas. 18F- DCFPyl Injection will be administered prior to the PSMA PET/CT via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access under the direct supervision of study personnel.
Trial: NCT06535685
Drug: Romiplostim
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Enrolled patients will be given Romiplostim (20 µg/kg subcutaneously once a week) for a minimum of 3 months.
Trial: NCT04759820
Drug: injecting Carbon Nanoparticles Suspension
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injecting Carbon Nanoparticles Suspension for lymph node detection
Trial: NCT04759820
Drug: Injecting indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injecting indocyanine green for lymph node detection
Trial: NCT06555237
Drug: Trametinib tablet
RxNorm normalized name: Trametinib Tablets
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametynib orally once daily in 0,025mg/kg dose
Trial: NCT05059418
Drug: Clonazepam 0.5 MG
RxNorm normalized name: clonazepam 0.5 MG
DrugBank: Clonazepam (DB01068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical treatment of oral mucosa with lozenge pill
Trial: NCT05059418
Drug: Capsaicin Topical
RxNorm normalized name: capsaicin topical
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical treatment of oral mucosa with capsaicin rinse
Trial: NCT05255913
Drug: Nanosilver
RxNorm normalized name: Nanosilver
DrugBank: Silver (DB12965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preventive material for arresting caries
Trial: NCT05255913
Drug: Silver diamine fluoride
RxNorm normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: preventive material for arresting caries
Trial: NCT06520319
Drug: 68Ga-MGS5
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient received a single intravenous injection of 68Ga-DOTATATE (2-4 mCi) and underwent PET/CT scanning 40-60 minutes after the injection. Or receive one intravenous injection of 68Ga-MGS5 and undergo two PET/CT scans at 1 and 2 hours post-injection, respectively.
Trial: NCT06055829
Drug: Insulin injection and blood glucose
RxNorm normalized name: glucose Injection
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The FreeStyle Libre sensor continuously measures glucose every minute and saves the glucose data. Scan the sensor at least every 8 hours for a full glycemic profile. The below data is displayed after a typical 1-second scan of the FreeStyle LibreLink app or FreeStyle Libre reader via the sensor:
Trial: NCT05127421
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream 1.5% applied twice a day (BID)
Trial: NCT05834764
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib after anti-HER2 therapy（Trastuzumab combined with Pertuzumab or T-DM1）
Trial: NCT06394518
Drug: TNP-2092 for injection
RxNorm normalized name: TNP-2092
DrugBank: TNP-2092 (DB16312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study had 3 dose groups, a 200 mg single dose group (low-dose group), a 300 mg single and multiple dose continuous dose group (medium-dose group), and 400 mg single dose group (high-dose group)
Trial: NCT05403541
Drug: Batoclimab 680 mg SC weekly
RxNorm normalized name: selinexor
DrugBank: Batoclimab (DB16104)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Trial: NCT05403541
Drug: Batoclimab 340 mg SC weekly
RxNorm normalized name: selinexor
DrugBank: Batoclimab (DB16104)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Trial: NCT05403541
Drug: Batoclimab 340 mg SC bi-weekly
RxNorm normalized name: selinexor
DrugBank: Batoclimab (DB16104)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Trial: NCT06459921
Drug: SOX+Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients would be allocated to the SOX+Sintilimab group.
Trial: NCT06459921
Drug: FLOT+Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients would be allocated to the FLOT+Sintilimab group.
Trial: NCT05284994
Drug: TQ-B3525 Tablets, Osimertinib Mesylate Tablets
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.
Trial: NCT05005975
Drug: MT-7117
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-7117
Trial: NCT04626791
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04626791
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT04626791
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04626791
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05354700
Drug: HLX07
RxNorm normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX07 is a recombinant humanized anti-EGFR monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
Trial: NCT05354700
Drug: HLX10
RxNorm normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX10 is a recombinant humanized anti-PD-1 monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
Trial: NCT05354700
Drug: carboplatin and etoposide
RxNorm normalized name: Carboplatin
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapeutics
Trial: NCT05388903
Drug: DS-2325a
RxNorm normalized name: DS-2325a
DrugBank: DS-2325a (DB18134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection (starting dose 30 mg)
Trial: NCT05388903
Drug: DS-2325a
RxNorm normalized name: DS-2325a
DrugBank: DS-2325a (DB18134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion (starting dose 100 mg)
Trial: NCT02635841
Drug: Deferiprone
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ferriprox (deferiprone) 100 mg/mL oral solution
Trial: NCT04647526
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone)
Trial: NCT04647526
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide (160 mg orally qd)
Trial: NCT05043649
Drug: Camsirubicin
RxNorm normalized name: Camsirubicin
DrugBank: Camsirubicin (DB13103)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose escalation of camsirubicin will start at 265 mg/m2, with dose increments of 50% until a Grade 2 non-hematologic toxicity is observed at which point subsequent dose escalations will be in increments of 25% until an MTD is identified in patients with ASTS.
Trial: NCT05084872
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be treated by hydroxychloroquine at a dose of 6 to 6.5mg/kg/day during 12 month
Trial: NCT00006154
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg tablets equaling 1600 mg daily
Trial: NCT00006154
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg liquid capsules equaling 400 mg daily
Trial: NCT00006154
Drug: Abacavir sulfate
RxNorm normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.
Trial: NCT00006154
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg capsules equaling 600 mg daily
Trial: NCT00006154
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-40 mg capsules equaling 60 or 80 mg daily
Trial: NCT00006154
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250-400 mg E.coated tablets equaling 250 or 400 mg daily
Trial: NCT00006154
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection equaling 15 x 10\^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.
Trial: NCT04475744
Drug: G-CSF treatment for Bone marrow derived stem cell Mobilization
RxNorm normalized name: G-CSF (CHO cell derived)
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mobilization treatment. On the fifth day, collection will be started.
Trial: NCT06427785
Drug: Remimazolam besylate
RxNorm normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Thirty patients underwent elective lower extremity surgery receive spinal anesthesia, and then remimazolam besylate was given intravenously with an induction dose of 3mg/min. When the MOAA/S (Modified Observer's Assessment of Alertness/Sedation) score was ≤1, remimazolam besylate was maintained at 1mg/min for 24min, and finally stopped. Wavelet index, MOAA/S score, blood pressure, heart rate, respiratory rate, and pulse oxygen saturation were continuously monitored during the period.
Trial: NCT04633057
Drug: TJ101
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive TJ101 1.2 mg/kg once a week until 52 weeks back site, investigator evaluate effectiveness and safety.
Trial: NCT04146571
Drug: Ensartinib
RxNorm normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, ALK inhibitor
Trial: NCT05089344
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: growth hormone
Trial: NCT05089344
Drug: Clomiphene citrate daily and recombinant FSH (Gonal-F®)
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate daily and recombinant FSH (Gonal-F®)
Trial: NCT05450432
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants will start treatment including two ketamine infusion visits per week during the acute phase, for up to eight ketamine infusion visits. Participants will then be transitioned to maintenance with intranasal esketamine.
Trial: NCT01151592
Drug: Iron Sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron Sucrose, 1000 mg cumulative dose to be administered per the US package insert.
Trial: NCT06102252
Drug: Paclitaxel/epirubcin/carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: adjuvant treatment in endometrial carcinoma
Trial: NCT06102252
Drug: Paclitaxel/carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose dense paclitaxel/carboplatin
Trial: NCT04755712
Drug: Sodium Chloride Injection
RxNorm normalized name: Sodium Chloride Injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of Sodium chloride at the usual quadratum lumburum block 2 (QLB2) injection site under ultrasound (sham-QLB2).
Trial: NCT04755712
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine via pump (patient controlled analgesia)
Trial: NCT05450432
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After one month from the eighth ketamine infusion visit, participants will initiate weekly esketamine for 12 weeks, for a total of 13 esketamine treatments. The esketamine visits will happen as per standard of care at the clinic and as instructed by the SPRAVATO Risk Evaluation and Mitigation Strategy.
Trial: NCT06013995
Drug: BMS-986326
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04667234
Drug: AMG 510
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an oral tablet.
Trial: NCT06098209
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h.
Trial: NCT06098209
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive propofol 0.3-4 mg/kg/h.
Trial: NCT05678192
Drug: oral menopausal hormone therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dydrogesterone 10 mg + Estradiol 1 mg/Dydrogesterone 5 mg + Estradiol 1 mg
Trial: NCT05678192
Drug: transdermal menopausal hormone therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol 1,5 mg + Progesterone 200 mg/Estradiol 1,5 mg + Progesterone 100 mg
Trial: NCT05051865
Drug: camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: camrelizumab combined with SHR1020 for advanced melanoma
Trial: NCT04853524
Drug: JNJ-56136379
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-56136379 tablets will be administered orally.
Trial: NCT04853524
Drug: Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)
RxNorm normalized name: bictegravir / emtricitabine / tenofovir alafenamide
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A combination of BIC, FTC and TAF will be administered orally.
Trial: NCT05802238
Drug: Tranexamic acid (TXA)
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gram of TXA in 10mg single-dose ampule (100mg/mL) administered 10 minutes prior to surgery
Trial: NCT06227585
Drug: Bevonescein
RxNorm normalized name: Bevonescein
DrugBank: Bevonescein (DB19021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive a single dose of bevonescein 500 mg via IV infusion 1-5 hours before surgery.
Trial: NCT05256056
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: efficacy of bupivacaine in different volumes
Trial: NCT05085028
Drug: Pembrolizumab 25 MG/ML [Keytruda]
RxNorm normalized name: pembrolizumab 25 MG/ML [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab to be given at 400mg intravenous over 5 different frequencies
Trial: NCT04767633
Drug: split dose vs standard dose of sodium pico sulfate plus magnesium sulfate in children for bowel cleansing
RxNorm normalized name: magnesium sulfate / potassium sulfate / sodium sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The preparations will be dispensed by a nurse who carefully explained how the products should be taken, emphasising the importance of complete intake of the solution to ensure a safe and effective procedure. Moreover, each patient will be provided with dietary instructions: low residue diet for 3 days before colonoscopy. During and after bowel preparation, solid food will not be allowed. Clear liquid could be taken until 2 hours before the procedure. All colonoscopy will be performed between 11:00 and 15:00 by two endoscopists.
Trial: NCT03745664
Drug: Methylprednisolone Sodium Succinate
RxNorm normalized name: Methylprednisolone Sodium Succinate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During hospitalization, 40 mg of methylprednisolone (20 mg/ml) will be given intravenously twice a day (20 mg every 12 hours).
Trial: NCT01297933
Drug: Omegaven
RxNorm normalized name: Omegaven
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
Trial: NCT05603039
Drug: QL1706
RxNorm normalized name: QL1706
DrugBank: QL1706 (DB17562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
Trial: NCT05603039
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
Trial: NCT06067412
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Efficacy in fits
Trial: NCT06670690
Drug: Atenolol 50 MG
RxNorm normalized name: atenolol 50 MG
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will be premedicated with atenolol (50mg)
Trial: NCT06670690
Drug: Propranolol Pill
RxNorm normalized name: propranolol Pill
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will be premedicated with propranolol (10mg)
Trial: NCT06670690
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patients will be premedicated with Ivabradine (5mg)
Trial: NCT05501860
Drug: AG-920
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-920 Sterile Topical Ophthalmic Solution
Trial: NCT06630871
Drug: Distitamab Vedotin in combination with Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the day after the initial TURBt procedure, use trastuzumab (200mg)+ Distitamab Vedotin (120mg \[≤ 60Kg\] or 2.0mg/Kg \[\>60Kg\]) every 3 weeks (Q3W). Simultaneously arrange for the patient to complete a second TURBt within 6 weeks, and continue to use 3 courses of Trastuzumab+Vediximab (Q3W) after surgery until the endpoint of 3-year follow-up
Trial: NCT00001009
Drug: Dextran sulfate
RxNorm normalized name: dextran sulfate
DrugBank: Dextran (DB09255)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05198752
Drug: Neoantigen mRNA Personalised Cancer SW1115C3
RxNorm normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection
Trial: NCT04852081
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib is in the form of oral capsules. Palbociclib, capsule, 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food
Trial: NCT04852081
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib, tablets, 600mg orally (three 200 mg tablets)taken once daily with or without food for 21 consecutive days followed by 7 days off treatment
Trial: NCT04852081
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abemaciclib in combination with fulvestrant or an aromatase inhibitor: 150 mg twice daily Abemaciclib as monotherapy: 200 mg twice daily. (2.1)
Trial: NCT04852081
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
Trial: NCT04852081
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole will be dosed daily at a fixed dose of 1 mg/day throughout the study.
Trial: NCT04852081
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen will be dosed daily at a fixed dose of 20 mg/day throughout the study.